Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:129387379" >
Smokers run increas...
Smokers run increased risk of developing anti-natalizumab antibodies
-
- Hedstrom, AK (författare)
- Karolinska Institutet
-
Alfredssoni, L (författare)
-
- Ryner, ML (författare)
- Karolinska Institutet
-
visa fler...
-
- Fogdell-Hahn, A (författare)
- Karolinska Institutet
-
- Hillert, J (författare)
- Karolinska Institutet
-
- Olsson, T (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2013-12-05
- 2014
- Engelska.
-
Ingår i: Multiple sclerosis (Houndmills, Basingstoke, England). - : SAGE Publications. - 1477-0970 .- 1352-4585. ; 20:8, s. 1081-1085
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Smoking may contribute to the induction of neutralizing antibodies to interferon β-1a. Objective: In this study, we aimed to investigate the influence of smoking on the risk of developing antibodies to natalizumab, another biological drug in the treatment of multiple sclerosis. Methods: This report is based on 1338 natalizumab-treated multiple sclerosis patients included in either of two Swedish case-control studies in which information on smoking habits was collected. Using logistic regression, patients with different smoking habits were compared regarding risk of developing anti-natalizumab antibodies, by calculating odds ratios with 95% confidence intervals. Results: Compared with nonsmokers, the odds ratio of developing anti-natalizumab antibodies was 2.4 (95% CI 1.2–4.4) for patients who smoked at the time of screening, and a significant trend showed higher risk of developing antibodies with higher intensity of smoking. When smoking within two years prior to screening was considered, the odds ratio of developing anti-natalizumab antibodies was 2.7 (1.5–5.1). Interpretations: The finding strengthens our hypothesis of the lungs as immune-reactive organs on irritation in relation to autoimmune responses, and may also be of clinical relevance since antibodies against natalizumab abrogate the therapeutic effect of the treatment.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas